Mumbai, June 23 -- The revised target price implies a potential upside of about 11.6% from the current market price.

The brokerage remains optimistic on Emcure's growth prospects and expects the company to deliver low- to mid-teen revenue growth in FY27. It also forecasts EBITDA margin expansion of 75-100 basis points during the year.

According to the brokerage, margin improvement is likely to be driven by higher productivity of the company's field force in India and new product launches across key international markets.

The brokerage highlighted Emcure's focus on research and development-backed products as a key pillar of its long-term growth strategy.

Reflecting its improved outlook, the brokerage raised its earnings per share (EPS)...